These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16029069)

  • 21. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
    Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
    Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
    Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
    Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
    Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
    Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
    AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
    Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
    Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
    Jullien V; Tréluyer JM; Rey E; Jaffray P; Krivine A; Moachon L; Lillo-Le Louet A; Lescoat A; Dupin N; Salmon D; Pons G; Urien S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3361-6. PubMed ID: 16048948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
    Kappelhoff BS; Rosing H; Huitema AD; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 792(2):353-62. PubMed ID: 12860043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
    Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
    J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
    Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
    Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.
    Mukonzo JK; Nanzigu S; Rekić D; Waako P; Röshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
    Clin Pharmacokinet; 2011 Aug; 50(8):531-40. PubMed ID: 21740076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
    Burger D; van der Heiden I; la Porte C; van der Ende M; Groeneveld P; Richter C; Koopmans P; Kroon F; Sprenger H; Lindemans J; Schenk P; van Schaik R
    Br J Clin Pharmacol; 2006 Feb; 61(2):148-54. PubMed ID: 16433869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.
    Villani P; Regazzi MB; Castelli F; Viale P; Torti C; Seminari E; Maserati R
    Br J Clin Pharmacol; 1999 Nov; 48(5):712-5. PubMed ID: 10594473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
    J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
    Veldkamp AI; van Heeswijk RP; Meenhorst PL; Mulder JW; Lange JM; Beijnen JH; Hoetelmans RM
    J Chromatogr B Biomed Sci Appl; 1999 Oct; 734(1):55-61. PubMed ID: 10574190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects.
    Ståhle L; Moberg L; Svensson JO; Sönnerborg A
    Ther Drug Monit; 2004 Jun; 26(3):267-70. PubMed ID: 15167626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.